These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
188 related items for PubMed ID: 12648401
1. [Therapy effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats]. Yan M, Meng FL, Lu RJ, Jia XQ, Zhao XC. Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):86-9. PubMed ID: 12648401 [Abstract] [Full Text] [Related]
2. [Effects of tea polyphennols on hepatic lipase activity in rabbits with fatty liver]. Zhang XG, Chen YZ, Lei H, Wang ZB. Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):77-9. PubMed ID: 12648397 [Abstract] [Full Text] [Related]
3. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Hong XZ, Li LD, Wu LM. Clin Exp Pharmacol Physiol; 2007 Feb; 34(1-2):27-35. PubMed ID: 17201732 [Abstract] [Full Text] [Related]
4. Therapeutic effect of osthole on hyperlipidemic fatty liver in rats. Zhang Y, Xie ML, Zhu LJ, Gu ZL. Acta Pharmacol Sin; 2007 Mar; 28(3):398-403. PubMed ID: 17303003 [Abstract] [Full Text] [Related]
5. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA. Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709 [Abstract] [Full Text] [Related]
6. [Effects of total glucosides of paeony on enhancing insulin sensitivity and antagonizing nonalcoholic fatty liver in rats]. Zheng LY, Pan JQ, Lv JH. Zhongguo Zhong Yao Za Zhi; 2008 Oct; 33(20):2385-90. PubMed ID: 19157135 [Abstract] [Full Text] [Related]
7. Fenofibrate prevents orotic acid--induced hepatic steatosis in rats. Ferreira AV, Parreira GG, Porto LC, Mario EG, Delpuerto HL, Martins AS, Botion LM. Life Sci; 2008 Apr 09; 82(15-16):876-83. PubMed ID: 18374364 [Abstract] [Full Text] [Related]
8. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, Herman ZS. Int J Clin Pharmacol Ther; 1998 Jun 09; 36(6):345-9. PubMed ID: 9660044 [Abstract] [Full Text] [Related]
9. [A study on the preventive effect of Lycium barbarum polysaccharide on the development of alcoholic fatty liver in rats and its possible mechanisms]. Gu S, Wang PL, Jiang R. Zhonghua Gan Zang Bing Za Zhi; 2007 Mar 09; 15(3):204-8. PubMed ID: 17407712 [Abstract] [Full Text] [Related]
10. [Experiment study of total anthraquinone in cassiae semen on lipid peroxidation and PPAR-gamma expression in liver tissues of rats with alcoholic fatty liver]. Luo X, Xu X, Huang C, Wu X, Liu J, Lan B, Xu J. Zhongguo Zhong Yao Za Zhi; 2011 Jun 09; 36(12):1654-9. PubMed ID: 22007555 [Abstract] [Full Text] [Related]
11. Dynamic expression of hepatic thioredoxin mRNA in rats with non-alcoholic fatty liver disease. Duan XY, Zhao HP, Fan JG. J Dig Dis; 2010 Apr 09; 11(2):94-100. PubMed ID: 20402835 [Abstract] [Full Text] [Related]
12. [Effects of calorie restriction on SIRT1 expression in liver of nonalcoholic fatty liver disease: experiment with rats]. Chen LL, Deng XQ, Li NX. Zhonghua Yi Xue Za Zhi; 2007 May 29; 87(20):1434-7. PubMed ID: 17785073 [Abstract] [Full Text] [Related]
13. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. Forcheron F, Abdallah P, Basset A, del Carmine P, Haffar G, Beylot M. Obesity (Silver Spring); 2009 Jul 29; 17(7):1381-9. PubMed ID: 19553925 [Abstract] [Full Text] [Related]
14. [Effect of polymorphism of human intestinal fatty acid binding protein gene on the therapeutic efficacy of fenofibrate]. Chang XT, Wang ZH, Du X, Dong MG, Hou LJ, Liu J, Wang J, Zhou JG. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Apr 29; 28(2):230-3. PubMed ID: 16733910 [Abstract] [Full Text] [Related]
15. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice. Carmona MC, Louche K, Nibbelink M, Prunet B, Bross A, Desbazeille M, Dacquet C, Renard P, Casteilla L, Pénicaud L. Int J Obes (Lond); 2005 Jul 29; 29(7):864-71. PubMed ID: 15917863 [Abstract] [Full Text] [Related]
16. Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats. Qin R, Zhang J, Li C, Zhang X, Xiong A, Huang F, Yin Z, Li K, Qin W, Chen M, Zhang S, Liang L, Zhang H, Nie H, Ye W. Arch Pharm Res; 2012 Jul 29; 35(7):1241-50. PubMed ID: 22864747 [Abstract] [Full Text] [Related]
17. [The lipid-lowering and antioxidative effects of marine collagen peptides]. Wang JB, Xie Y, Pei XR, Yang RY, Zhang ZF, Li Y. Zhonghua Yu Fang Yi Xue Za Zhi; 2008 Apr 29; 42(4):226-30. PubMed ID: 18763630 [Abstract] [Full Text] [Related]
18. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia. Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I. Kardiol Pol; 2004 Jun 29; 60(6):567-77. PubMed ID: 15334157 [Abstract] [Full Text] [Related]
19. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Diabetes Res Clin Pract; 2004 May 29; 64(2):137-51. PubMed ID: 15063607 [Abstract] [Full Text] [Related]
20. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Clin Ther; 2004 Oct 29; 26(10):1599-607. PubMed ID: 15598476 [Abstract] [Full Text] [Related] Page: [Next] [New Search]